Treatment of an extracorporeal stream of blood with a dialyzable chemotherapeutic and a fluorescable tracer

Patent 4329986 Issued on May 18, 1982. Estimated Expiration Date:

June 14, 1999. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.

Abstract Claims Description Full Text

Patent References

B409220

2650709

3459176

3483867

3719182

3785772

3814939

3833724

4081372

Method and apparatus for measuring the content of a low-molecular weight compound in a complex medium Patent #: 4123353
Issued on: 10/31/1978
Inventor: Hakansson , et al.

Inventor

Babb, Albert L.

Assignee

Biomedics, Inc.

Application

No. 06/048334 filed on 06/14/1979

US Classes:

604/5.04, Toxic material removed210/645, Biological fluid (e.g., blood, urine, etc.)210/646, Hemodialysis210/647, Maintaining critical concentration(s)210/648, Including regenerating or rehabilitating the extracting liquid in liquid/liquid solvent or colloidal extraction210/651, Removing specified material250/302, RADIATION TRACER METHODS250/304, METHODS INCLUDING SEPARATION OR NONRADIANT TREATMENT OF TEST MATERIALS436/172, With fluorescence or luminescence600/432, Piston-type ram forces material into body600/436, Nuclear radiation (e.g., radioactive emission, etc.)600/469, Detecting emboli600/476, Visible light radiation604/28, Method604/507Therapeutic material introduced into or removed from vasculature

Examiners

Primary: Fagelson, Anna P.

International Classes

A61K 33/00 (20060101)
G01N 33/487 (20060101)

Abstract

A therapeutic composition suitable for extracorporeal treatment of whole blood comprises a dialyzable chemotherapeutic agent and a dialyzable fluorescable tracer means. The removal rate of the fluorescable tracer compound from treated blood during hemodialysis is a function of the removal rate of unreacted chemotherapeutic agent present. The residual chemotherapeutic agent concentration after hemodialysis is ascertained by measuring the concentration of the fluorescable tracer compound in a dialysate using fluorometric techniques.

Other References

Babb, Carbamylated Red Cell Distributions in Blood Treated Extracorporeally with Cyanate, Final Report Prepared for Div. of Blood & Dis. Resources Nat. Heart, Lung & Blood Inst., Bethesda, Md., Contract No. 1-HB-6-2962, U.S. NTIS PB Rep. 1977-PB274862, Jul. 1977
Rabb, Chem. Abs., vol. 89, 1978, Ab. No. 613